PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage precision oncology company developing small-molecule therapies that target the p53 tumor-suppressor pathway, a mechanism implicated in roughly half of all cancers. Its lead asset, rezatapopt, is advancing toward a potential regulatory filing, and Wall Street analysts currently carry price targets far above the stock's recent trading level. The central question for investors is whether shares can climb to the average analyst price target of $4.20.
Five verifiable analyst price targets were reviewed. The lowest, at $3, comes from Ladenburg Thalmann (reiterated Buy in August 2026). Two firms, Evercore ISI and Craig-Hallum, each reiterated Buy ratings with $4 targets in September 2026. H.C. Wainwright reiterated a Buy with a $5 target in September 2026, and Oppenheimer maintained Buy with a $5 target in May 2026. Averaging these five targets yields $4.20, which serves as the central target used here. It should be read as a calculated mean, not an official published consensus.
The narrow $3–$5 band masks meaningful disagreement about value. The lower targets reflect the reality that rezatapopt is still pre-approval, with no commercial revenue, while the higher targets credit the durability of the ovarian-cancer response data and a credible path to accelerated approval. Notably, several targets have been trimmed over time, reflecting share-price declines and dilution, so even the bullish figures have moved down.
PMVP trades around $1.24, near the lower end of its 52-week range. Reaching $4.20 would require an increase of roughly 240%, which is a very large move by any standard. For a pre-revenue biotech, such a move would almost certainly need to be driven by discrete catalysts rather than steady earnings growth.
The most plausible path runs through the regulatory milestones: a full update on the Phase 2 PYNNACLE pivotal cohorts expected in the fourth quarter of 2026, followed by a planned NDA submission in the first quarter of 2027. Positive data and an accepted filing could prompt a re-rating, because a company without meaningful revenue is valued primarily on the probability and size of future commercial success.
The stock has been in a prolonged downtrend and sits near the low end of a 52-week range that spans roughly $0.81 to $1.84. The $1.00 level is an important psychological support, while the prior 52-week high near $1.84 represents a meaningful resistance zone that shares would need to clear before any sustained move toward $4.20 could develop. Given the gap between the current price and the target, traditional technical support and resistance levels matter less than binary clinical and regulatory catalysts.
Analyst price targets typically reflect a research horizon of roughly 12 months, though the actual horizon varies by firm and was not always disclosed. For PMVP, the most important near-term items are the fourth-quarter 2026 update on all PYNNACLE Phase 2 cohorts at the ENA 2026 conference, the planned first-quarter 2027 NDA submission, any further FDA interactions, and the company's cash position and financing decisions.
For traders tracking volatile clinical-stage names like PMVP, AI Daily Buy/Sell Signals from Tickeron can provide a useful complement to fundamental research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows.
The $4.20 central target is a calculated average of five analyst targets ranging from $3 to $5, and it represents roughly 240% upside from a recent price near $1.24. The bull case rests on encouraging rezatapopt ovarian-cancer data and a clear path toward an accelerated-approval NDA filing, while the bear case centers on single-asset risk, dilution, and the ever-present possibility of a clinical or regulatory setback. Analysts are uniformly constructive, but the wide gap between the current price and the target underscores the speculative nature of the setup. Investors should watch the fourth-quarter 2026 data update and the 2027 filing timeline before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
A.I.dvisor indicates that over the last year, PMVP has been loosely correlated with CLLS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PMVP jumps, then CLLS could also see price increases.
| Ticker / NAME | Correlation To PMVP | 1D Price Change % | ||
|---|---|---|---|---|
| PMVP | 100% | +3.28% | ||
| CLLS - PMVP | 39% Loosely correlated | +24.32% | ||
| MTVA - PMVP | 35% Loosely correlated | -3.36% | ||
| CGEN - PMVP | 33% Loosely correlated | N/A | ||
| RCKT - PMVP | 32% Poorly correlated | +1.22% | ||
| SLDB - PMVP | 31% Poorly correlated | +6.00% | ||
More | ||||